Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term and near-term infants with a gestational age of more than 34 weeks~* Admitted to the Children's Hospital of Lucerne, Switzerland~* Suspected neonatal early-onset sepsis~* Antibiotic therapy~* Parental consent~Exclusion Criteria:~* Surgery in the first 3 days of life~* Severe congenital malformations~* Chromosomal abnormalities

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Procalcitonin group (Type: EXPERIMENTAL): Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
- Standard group (Type: NO_INTERVENTION): Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters

Based on this trial design, predict the completion outcome and termination type (if applicable).